Benutzer: Gast  Login
Dokumenttyp:
journal article 
Autor(en):
Herrmann, K; Wieder, HA; Buck, AK; Schöffel, M; Krause, BJ; Fend, F; Schuster, T; Meyer Zum Büschenfelde, C; Wester, HJ; Duyster, J; Peschel, C; Schwaiger, M; Dechow, T 
Titel:
Early Response Assessment Using 3'-Deoxy-3'-[18F]Fluorothymidine-Positron Emission Tomography in High-Grade Non-Hodgkin's Lymphoma. 
Abstract:
PURPOSE: To evaluate 3'-deoxy-3'-[(18)F]fluorothymidine-positron emission tomography (FLT-PET) for early monitoring response of high-grade non-Hodgkin's lymphoma to treatment with cyclophosphamide-adriamycin-vincristine-prednisone chemotherapy with or without rituximab immunotherapy (R-CHOP/CHOP). EXPERIMENTAL DESIGN: Twenty-two patients with histologically proven high-grade non-Hodgkin's lymphoma scheduled to undergo first line treatment with R-CHOP/CHOP were included. All patients received baseline imaging before therapy with FLT-PET. For noninvasive assessment of treatment response, FLT-PET was repeated at following time points: group 1 (n = 6), 1 and 6 weeks after R-CHOP/CHOP; group 2 (n = 16), 2 days after rituximab and 2 days after CHOP application. Emission images were acquired 45 min after injection of 300 to 370 MBq of FLT. FLT uptake was quantified by region-of-interest technique on a lesion basis. Maximum standardized uptake values (SUV) for FLT were calculated using circular region of interest (diameter, 1.5 cm). RESULTS: In all patients, morphologically proven lesions showed initially high FLT uptake (mean SUV, 8.1 +/- 3.9). In group 1, mean FLT SUV decreased 7 days after R-CHOP/CHOP by 77% (P< 0.001), the reduction in FLT SUV from baseline was 85% after 40 days (P = 0.003). In group 2, FLT uptake in patients without dexamethasone pretreatment revealed no significant reduction after rituximab (P = 0.3) but significantly decreased 2 days after CHOP to 32% compared with the baseline value (P = 0.004). CONCLUSIONS: Administration of R-CHOP/CHOP is associated with an early decrease in lymphoma FLT uptake. Interestingly, there was no reduction of FLT uptake after rituximab alone, indicating no early antiproliferative effect of immunotherapy. FLT-PET seems to be promising for early evaluation of drug effects in lymphoma. 
Zeitschriftentitel:
Clin Cancer Res 
Jahr:
2007 
Band / Volume:
13 
Heft / Issue:
12 
Seitenangaben Beitrag:
3552-8 
Sprache:
eng 
Print-ISSN:
1078-0432 
TUM Einrichtung:
Nuklearmedizinische Klinik und Poliklinik; ntgendiagnostik; r Allgemeine Pathologie und pathologische Anatomie; r Medizinische Statistik und Epidemiologie; III. Medizinische Klinik und Poliklinik